To include your compound in the COVID-19 Resource Center, submit it here.

Parsing FDA's Priorities

FDA presents ambitious strategic priorities but no performance metrics or costs

FDA's report on "Strategic Priorities, 2011-2015," released last week, stresses the importance of infusing the agency with cutting edge science, promoting biomedical innovation, and addressing the challenges posed by the globalization of drug supply chains.

But if the document's themes resonate with drug, diagnostics and medical device companies, as well as patients, it does not provide milestones or measurable objectives that would make it possible to assess the agency's progress toward attaining its goals.

FDA also

Read the full 740 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE